Sigrima 420mg (Pertuzumab SOLUTION) 420mg/14ml

Sigrima 420mg is a prescription medication containing pertuzumab, a targeted therapy solution for cancer treatment. Administered via injection, it belongs to the class of HER2 inhibitors used in combination therapies. This 420mg/14ml formulation is stored at 2-8°C. Always consult a healthcare provider for personalized guidance.

Strength

420mg/14ml

Storage

2-8°

Manufacturer / TM Owner

Zydus Life Sciences Ltd

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Pertuzumab is primarily used to treat certain types of breast cancer, including HER2-positive metastatic or early-stage cancers. It is often prescribed alongside other medications like trastuzumab and docetaxel to slow disease progression. This combination therapy targets specific cancer cells to improve treatment outcomes. Sigrima 420mg may also be used in neoadjuvant or adjuvant settings.

Side Effects

As a targeted therapy, pertuzumab works by binding to HER2 receptors on cancer cells, helping to block signals that promote tumor growth. Patients may experience general effects such as fatigue, nausea, or diarrhea, which vary by individual. Some may notice changes in heart function, requiring monitoring during treatment. These effects are typically managed under medical supervision.

Precautions & Warnings

Sigrima 420mg should be handled and administered by healthcare professionals in a clinical setting. Patients with known allergies to pertuzumab or its components should avoid this medication. Regular monitoring of heart function and blood counts is recommended during therapy. Pregnant or breastfeeding individuals should discuss risks with their doctor before use.

Avoid Interactions

Pertuzumab may interact with other medications, including certain chemotherapy drugs and cardiac therapies. Combining it with anthracyclines or other HER2-targeted agents could increase side effects like heart toxicity. Patients should inform their healthcare provider about all medications, supplements, or herbal products they are using. Alcohol and grapefruit products may also pose additional risks.

References

Frequently Asked Questions

Sigrima 420mg is used to treat HER2-positive breast cancer, often in combination with other cancer therapies.

It is given as an intravenous infusion by a healthcare professional in a clinical setting.

Common side effects may include fatigue, nausea, diarrhea, and potential changes in heart function.

Pregnant individuals should discuss risks with their doctor, as pertuzumab may harm an unborn baby.

Store Sigrima 420mg at 2-8°C and protect it from light until use.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.